SciSparc Ltd. (SPRC)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Oz Adler CPA | CEO & CFO | 422k | -- | 1987 |
| Mr. Itschak Shrem | President & Director | 268k | -- | 1947 |
| Dr. Adi Zuloff-Shani Ph.D. | Chief Technologies Officer | 325k | -- | 1969 |
SciSparc Ltd.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 2
Description
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
Corporate Governance
Upcoming Events
April 24, 2025 at 8:00 PM UTC
SciSparc Ltd. Earnings Date
Recent Events
April 1, 2025 at 12:00 AM UTC
425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
February 27, 2025 at 12:00 AM UTC
425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions